Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients

Table 2 Baseline characteristics, n (%)

	Control (n = 54)	Observation (n = 50)	χ2	P value
Gender			0.198	0.655
Male	43 (79.63)	38 (76.00)
Female	11 (20.37)	12 (24.00)
Age (years)			0.025	0.873
< 65	30 (55.56)	27 (54.00)
≥ 65	24 (44.44)	23 (46.00)
ECOG score			0.005	0.938
0	22 (40.74)	20 (40.00)
1-2	32 (59.26)	30 (60.00)
Tumor location			1.801	0.179
Stomach	21 (38.89)	26 (52.00)
Gastroesophageal junction	33 (61.11)	24 (48.00)
Surgical status			1.874	0.171
Yes	10 (18.52)	15 (30.00)
No	44 (81.48)	35 (70.00)
Liver metastasis			0.063	0.801
Yes	24 (44.44)	21 (42.00)
No	30 (55.56)	29 (58.00)
Peritoneal metastasis			0.068	0.793
Yes	16 (29.63)	16 (32.00)
No	38 (70.37)	34 (68.00)
HER-2 expression			0.497	0.480
IHC2 + (ISH positive)	18 (33.33)	20 (40.00)
IHC3 +	36 (66.67)	30 (60.00)
PD-L1 expression			0.292	0.588
Positive (CPS ≥ 1%)	22 (40.74)	23 (46.00)
Negative (CPS < 1%)	32 (59.26)	27 (54.00)
Chemotherapy regimen
XELOX	23 (42.59)	31 (62.00)
SOX	26 (48.15)	13 (26.00)
Cisplatin + Taxanes	5 (9.26)
Cisplatin + Nab-Paclitaxel		6 (12.00)

ECOG: Eastern Cooperative Oncology Group; HER-2: Human epidermal growth factor receptor 2; IHC: Immunohistochemistry; ISH: In situ hybridization; PD-L1: Programmed death-ligand 1; CPS: Combined positive score.